Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial
Su KP, Huang SY, Chiu TH, Huang KC, Huang CL, Chang HC, Pariante CM
The Journal of clinical psychiatry · 207 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Medical Research Council
Según 1 financiador declarado.
Publicación
- Publicado
- 2008-04-15 · J Clin Psychiatry · vol. 69 · número 4 · págs. 644–651
- Editorial
- Physicians Postgraduate Press, Inc.
- Citado
- 308 citas · más que el 100% de estudios similares · 21.5× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 67 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Maternal Mental Health During Pregnancy and Postpartum · Treatment of Major Depression
- Palabras clave
- omega-3 fatty acids, polyunsaturated fatty acids, major depressive disorder, perinatal depression, antenatal depression, antidepressant monotherapy, maternal depression, fetal development, treatment response and remission, drug safety in pregnancy
- MeSH
- humans, pregnancy complications, fatty acids, omega-3, chromatography, gas, double-blind method, pregnancy, diagnostic and statistical manual of mental disorders, adult, female, surveys and questionnaires, major depressive disorder
7 autores
- Kuan‐Pin Su🇬🇧🇹🇼King's College London; China Medical University; China Medical University Hospital; Taipei Medical University
- Shih‐Yi Huang🇹🇼Taipei Medical University
- Tsan-Hung Chiu🇹🇼China Medical University
- Kuo-Cherh Huang
- Chieh‐Liang Huang🇹🇼China Medical University
- Hui-Chih Chang🇬🇧🇹🇼King's College London; Taipei Medical University
- Carmine Maria Pariante
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Perinatal depression is common, and treatment remains challenging. Depression has been reported to be associated with the abnormality of omega-3 polyunsaturated fatty acids (PUFAs). A profound decrease of omega-3 PUFAs in the mother during pregnancy is associated with the higher demand of fetal development and might precipitate the occurrence of depression. In this study, we examined the efficacy of omega-3 PUFA monotherapy for the treatment of depression during pregnancy.
Method
From June 2004 to June 2006, we conducted an 8-week, double-blind, placebo-controlled trial comparing omega-3 PUFAs (3.4 g/d) with placebo in pregnant women with major depressive disorder (DSM-IV criteria). No psychotropic agent was given 1 month prior to or during the study period. The Hamilton Rating Scale for Depression (HAM-D) was scored every other week as the primary measurement of efficacy, while the Edinburgh Postnatal Depression Scale (EPDS) and Beck Depression Inventory (BDI) were secondary measures.
Results
Thirty-six subjects were randomly assigned to either omega-3 PUFAs or placebo, and 33 among them were evaluated in more than 2 visits. A total of 24 subjects completed the study. As compared to the placebo group, subjects in the omega-3 group had significantly lower HAM-D scores at weeks 6 (p = .001) and 8 (p = .019), a significantly higher response rate (62% vs. 27%, p = .03), and a higher remission rate, although the latter did not reach statistical significance (38% vs. 18%, p = .28). At the study end point, subjects in the omega-3 group also had significantly lower depressive symptom ratings on the EPDS and BDI. The omega-3 PUFAs were well tolerated and there were no adverse effects on the subjects and newborns.
Conclusions
Omega-3 PUFAs may have therapeutic benefits in depression during pregnancy. In regard to the safety issue and psychotherapeutic effect, as well as health promotion to mothers and their newborns, it is worthy to conduct replication studies in a larger sample with a broad regimen of omega-3 PUFAs in pregnant women with depression.
Trial registration
clinicaltrials.gov Identifier: NCT00618865.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.